Ranbaxy Denies Fraudulent Conduct Alleged By FDA As Rumors Swirl About Daiichi Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Charges stem from 2006 inspection issues Daiichi knew about when it offered to buy a majority stake in the Indian firm.
You may also be interested in...
Daiichi Sankyo Ranbaxy Acquisition Very Much Alive
Details of tender offer at 40 percent premium revealed.
Daiichi Sankyo Ranbaxy Acquisition Very Much Alive
Details of tender offer at 40 percent premium revealed.
Ranbaxy Sees Light At The End Of DoJ Investigation Tunnel
Information Ranbaxy is giving FDA will clear its name, CEO says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: